ATA Guidelines: Do Patients with Stage I Thyroid Cancer Benefit From 131 I?
Authors:
- Steven OrlovSOSteven Orlov
- David OrlovDODavid Orlov
- Michael ShaytzagMSMichael Shaytzag
- Mark DowarMDMark Dowar
- Vafa TabatabaieVTVafa Tabatabaie
- Philip DwekPDPhilip Dwek
- Jonathan YipJYJonathan Yip
- Cindy HuCHCindy Hu
- Jeremy L. FreemanJFJeremy L. Freeman
- Paul G. WalfishPWPaul G. Walfish
- David S. CooperDCDavid S. Cooper
- Gerard M. DohertyGDGerard M. Doherty
- 1 June 2007
- journal article
- research article
- Published by SAGE Publications in Thyroid®
- Vol. 17 (6) , 595-597
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Guidance for GuidelinesNew England Journal of Medicine, 2007
- Outcomes of Patients with Differentiated Thyroid Carcinoma Following Initial TherapyThyroid®, 2006
- Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinomaJournal of Surgical Oncology, 2006
- Second Primary Cancers in Thyroid Cancer Patients: A Multinational Record Linkage StudyThe Journal of Clinical Endocrinology & Metabolism, 2006
- Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines TaskforceThyroid®, 2006
- Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 yearsClinical Endocrinology, 2005
- A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2004
- Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- Leukaemias and cancers following iodine-131 administration for thyroid cancerBritish Journal of Cancer, 1997